Initial step towards developing fully human antibody therapeutics and diagnostics for COVID-19 has been made at Utrecht University.
Researchers at Utrecht University, Erasmus Medical Center and Harbour BioMed (HBM) reported that they have identified a fully human monoclonal antibody that prevents the SARS-CoV-2 (COVID-19) virus from infecting cultured cells. The discovery, published online in Nature Communications, is an initial step towards developing a fully human antibody to treat or prevent the respiratory disease COVID-19 caused by the novel coronavirus SARS-CoV-2.
The COVID-19 pandemic has spread rapidly across the globe infecting more than 3.3 million people worldwide and killing more than 235,000 people so far.
“This research builds on the work our groups have done in the past on antibodies targeting the SARS-CoV that emerged in 2002/2003,” said Berend-Jan Bosch, Associate Professor, Research leader at Utrecht University, and co-lead author of the Nature Communications study. “Using this collection of SARS-CoV antibodies, we identified an antibody that also neutralizes infection of SARS-CoV-2 in cultured cells. Such a neutralizing antibody has potential to alter the course of infection in the infected host, support virus clearance or protect an uninfected individual that is exposed to the virus.”
Researchers at Utrecht University, Erasmus Medical Center and Harbour BioMed (HBM) reported that they have identified a fully human monoclonal antibody that prevents the SARS-CoV-2 (COVID-19) virus from infecting cultured cells. The discovery, published online in Nature Communications, is an initial step towards developing a fully human antibody to treat or prevent the respiratory disease COVID-19 caused by the novel coronavirus SARS-CoV-2.
The COVID-19 pandemic has spread rapidly across the globe infecting more than 3.3 million people worldwide and killing more than 235,000 people so far.
“This research builds on the work our groups have done in the past on antibodies targeting the SARS-CoV that emerged in 2002/2003,” said Berend-Jan Bosch, Associate Professor, Research leader at Utrecht University, and co-lead author of the Nature Communications study. “Using this collection of SARS-CoV antibodies, we identified an antibody that also neutralizes infection of SARS-CoV-2 in cultured cells. Such a neutralizing antibody has potential to alter the course of infection in the infected host, support virus clearance or protect an uninfected individual that is exposed to the virus.”

Credit: Utrecht University.
Bosch noted that the antibody binds to a domain that is conserved in both SARS-CoV and SARS-CoV-2, explaining its ability to neutralize both viruses. “This cross-neutralizing feature of the antibody is very interesting and suggests it may have potential in mitigation of diseases caused by future-emerging related coronaviruses.”
Potential COVID-19 treatment
“This discovery provides a strong foundation for additional research to characterize this antibody and begin development as a potential COVID-19 treatment,” said Frank Grosveld, PhD. co-lead author on the study, Academy Professor of Cell Biology, Erasmus Medical Center, Rotterdam and Founding Chief Scientific Officer at Harbour BioMed. “The antibody used in this work is ‘fully human,’ allowing development to proceed more rapidly and reducing the potential for immune-related side effects.” Conventional therapeutic antibodies are first developed in other species and then must undergo additional work to ‘humanize’ them. The antibody was generated using Harbour BioMed’s H2L2 transgenic mouse technology.
“This is groundbreaking research,” said Dr. Jingsong Wang, Founder, Chairman & Chief Executive Officer of HBM. “Much more work is needed to assess whether this antibody can protect or reduce the severity of disease in humans. We expect to advance development of the antibody with partners. We believe our technology can contribute to addressing this most urgent public health need and we are pursuing several other research avenues.”
Contacts and sources:
Myrna Tinbergen
Publication: A human monoclonal antibody blocking SARS-CoV-2 infection. Chunyan Wang, Wentao Li, Dubravka Drabek, Nisreen M. A. Okba, Rien van Haperen, Albert D. M. E. Osterhaus, Frank J. M. van Kuppeveld, Bart L. Haagmans, Frank Grosveld, Berend-Jan Bosch. Nature Communications, 2020; 11 (1) DOI: 10.1038/s41467-020-16256-y
Bosch noted that the antibody binds to a domain that is conserved in both SARS-CoV and SARS-CoV-2, explaining its ability to neutralize both viruses. “This cross-neutralizing feature of the antibody is very interesting and suggests it may have potential in mitigation of diseases caused by future-emerging related coronaviruses.”
Potential COVID-19 treatment
“This discovery provides a strong foundation for additional research to characterize this antibody and begin development as a potential COVID-19 treatment,” said Frank Grosveld, PhD. co-lead author on the study, Academy Professor of Cell Biology, Erasmus Medical Center, Rotterdam and Founding Chief Scientific Officer at Harbour BioMed. “The antibody used in this work is ‘fully human,’ allowing development to proceed more rapidly and reducing the potential for immune-related side effects.” Conventional therapeutic antibodies are first developed in other species and then must undergo additional work to ‘humanize’ them. The antibody was generated using Harbour BioMed’s H2L2 transgenic mouse technology.
“This is groundbreaking research,” said Dr. Jingsong Wang, Founder, Chairman & Chief Executive Officer of HBM. “Much more work is needed to assess whether this antibody can protect or reduce the severity of disease in humans. We expect to advance development of the antibody with partners. We believe our technology can contribute to addressing this most urgent public health need and we are pursuing several other research avenues.”
Contacts and sources:
Myrna Tinbergen
Utrecht University
My online shop provides professional and customized pillow ! include linen cushion covers,french linen cushion covers,vintage cushion covers and other pillow!
ReplyDeleterustic pillows for couch
children's decorative pillows
pillow covers geometric
God bless Dr. USELU for his marvelous work in my life, I was diagnosed of HERPES SIMPLEX VIRUS since 2018 and I was taking my medications, I wasn't satisfied i needed to get the HERPES out of my system, I searched about some possible cure for HERPES i saw a comment about Dr. USELU , how he cured HERPES with his herbal medicine, I contacted him and he guided me. I asked for solutions, he started the remedy for my health, he sent me the medicine within 3 days. I took the medicine as prescribed by him and 2weeks later i was cured from HERPES contact him via email (dr.uselucaregiver@gmail.com) once again thanks to you Dr. USELU cure the flowing virus, contact his email or add him on whatsapp (+2349019328641) cancer cure
ReplyDeletediabetes cure
ringing ear
herpes cure
warts cure
HPV cure
HIV cure
get your ex back
pregnancy herbal medicine
Hepatitis
God bless Dr. USELU for his marvelous work in my life, I was diagnosed of HERPES SIMPLEX VIRUS since 2018 and I was taking my medications, I wasn't satisfied i needed to get the HERPES out of my system, I searched about some possible cure for HERPES i saw a comment about Dr. USELU , how he cured HERPES with his herbal medicine, I contacted him and he guided me. I asked for solutions, he started the remedy for my health, he sent me the medicine within 3 days. I took the medicine as prescribed by him and 2weeks later i was cured from HERPES contact him via email (dr.uselucaregiver@gmail.com) once again thanks to you Dr. USELU cure the flowing virus, contact his email or add him on whatsapp (+2348132015009) cancer cure
ReplyDeletediabetes cure
ringing ear
herpes cure
warts cure
HPV cure
HIV cure
get your ex back
pregnancy herbal medicine
Hepatitis